Literature DB >> 32623663

The impact of polycystic ovary syndrome and body mass index on the absorption of recombinant human follicle stimulating hormone.

Malinda S Lee1, Andrea Lanes2, Andrey V Dolinko3, Alexandra Bailin4, Elizabeth Ginsburg2.   

Abstract

PURPOSE: Women with polycystic ovary syndrome (PCOS) have an increased ovarian responsiveness to exogenous recombinant follicle stimulating hormone (rFSH) but also have high rates of obesity, which is known to affect serum FSH concentrations following exogenous injection. The purpose of this study was to compare rFSH absorption and ovarian response between lean and overweight/obese PCOS subjects and normo-ovulatory controls.
METHODS: Fourteen women with PCOS aged 18-42 years old with a BMI of 18.5-24.9 kg/m2 (normal) or 25.0-40.0 kg/m2 (overweight/obese) and eleven normo-ovulatory controls matched by age and BMI were included. After downregulation with oral contraceptives, participants were administered a single subcutaneous injection of 225 IU rFSH and underwent serial blood draws over 72 h.
RESULTS: Lean PCOS subjects exhibited a significantly higher area under the curve (AUC) of baseline-corrected serum FSH over 72 h when compared with overweight/obese PCOS subjects (183.3 vs 139.8 IU*h/L, p = 0.0002), and lean, normo-ovulatory women had a significantly higher AUC FSH when compared with overweight/obese, normo-ovulatory women (193.3 vs 93.8 IU*h/L, p < 0.0001). Within overweight/obese subjects, those with PCOS had a significantly higher AUC FSH compared with normo-ovulatory controls (p = 0.0002). Lean PCOS subjects similarly had the highest AUC of baseline-corrected estradiol (6095 pg h/mL), compared with lean normo-ovulatory subjects (1931 pg h/mL, p < 0.0001) and overweight/obese PCOS subjects (2337 pg h/mL, p < 0.0001).
CONCLUSION: Lean PCOS subjects exhibited significantly higher baseline-corrected FSH and estradiol levels following rFSH injection compared with overweight/obese PCOS subjects with similar ovarian reserve markers. Amongst overweight/obese subjects, those with PCOS had significantly higher FSH and E2 levels when compared with normo-ovulatory controls.

Entities:  

Keywords:  Body mass index; Follicle stimulating hormone; Obesity; Pharmacodynamics; Pharmacokinetics; Polycystic ovary syndrome

Mesh:

Substances:

Year:  2020        PMID: 32623663      PMCID: PMC7492314          DOI: 10.1007/s10815-020-01865-9

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  22 in total

1.  CLINICAL AND BIOCHEMICAL FEATURES OF POLYCYSTIC OVARIAN DISEASE.

Authors:  J W GOLDZIEHER; L R AXELROD
Journal:  Fertil Steril       Date:  1963 Nov-Dec       Impact factor: 7.329

2.  Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle-stimulating hormone.

Authors:  J Y le Cotonnec; E Loumaye; H C Porchet; V Beltrami; A Munafo
Journal:  Fertil Steril       Date:  1998-02       Impact factor: 7.329

3.  Factors associated with ovarian hyperstimulation syndrome (OHSS) and its effect on assisted reproductive technology (ART) treatment and outcome.

Authors:  Barbara Luke; Morton B Brown; Dean E Morbeck; Susan B Hudson; Charles C Coddington; Judy E Stern
Journal:  Fertil Steril       Date:  2009-07-09       Impact factor: 7.329

Review 4.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

Authors: 
Journal:  Hum Reprod       Date:  2004-01       Impact factor: 6.918

5.  Increased androgen response to follicle-stimulating hormone administration in women with polycystic ovary syndrome.

Authors:  Deborah S Wachs; Mickey S Coffler; Pamela J Malcom; Shunichi Shimasaki; R Jeffrey Chang
Journal:  J Clin Endocrinol Metab       Date:  2008-02-19       Impact factor: 5.958

6.  Androgen excess in women: experience with over 1000 consecutive patients.

Authors:  R Azziz; L A Sanchez; E S Knochenhauer; C Moran; J Lazenby; K C Stephens; K Taylor; L R Boots
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

7.  The prevalence and features of the polycystic ovary syndrome in an unselected population.

Authors:  Ricardo Azziz; Keslie S Woods; Rosario Reyna; Timothy J Key; Eric S Knochenhauer; Bulent O Yildiz
Journal:  J Clin Endocrinol Metab       Date:  2004-06       Impact factor: 5.958

8.  Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study.

Authors:  E S Knochenhauer; T J Key; M Kahsar-Miller; W Waggoner; L R Boots; R Azziz
Journal:  J Clin Endocrinol Metab       Date:  1998-09       Impact factor: 5.958

9.  Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin.

Authors:  C Bergh; B Carlsson; J H Olsson; U Selleskog; T Hillensjö
Journal:  Fertil Steril       Date:  1993-02       Impact factor: 7.329

10.  Metabolic regulation of androgen production by human thecal cells in vitro.

Authors:  R Nahum; K J Thong; S G Hillier
Journal:  Hum Reprod       Date:  1995-01       Impact factor: 6.918

View more
  1 in total

1.  The impact of hyperandrogenism on the outcomes of ovulation induction using gonadotropin and intrauterine insemination in women with polycystic ovary syndrome.

Authors:  Vu Ngoc Anh Ho; Toan Duong Pham; Nam Thanh Nguyen; Hieu Le Trung Hoang; Tuong Manh Ho; Lan Ngoc Vuong
Journal:  Clin Exp Reprod Med       Date:  2022-05-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.